The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Translational insights from the SEQTOR trial in pancreatic neuroendocrine tumors
Ramon Salazar, MD, PhD, Institut Català D’Oncologia, Barcelona, Spain, comments on the Phase III SEQTOR trial (NCT02246127), which evaluated treatment sequencing for advanced pancreatic neuroendocrine tumors (panNETs). Patients received either everolimus or streptozotocin plus 5-fluorouracil as first-line therapy. Genetic analysis revealed mutations in transcription, chromatin remodeling (DAXX), and tumor suppression genes, consistent with prior panNET studies. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
